Stem Cell Clinic

A Quarantine Trendsetter – Long Island Weekly News

By Stem Cell Doctors

Coronavirus (Image source: U.S. Department of State)

In my February column, I wrote about the fact that I had a stem cell transplant in early December 2019, about a month before I heard for the first time about the coronavirus.

The transplant entailed getting an unrelated donors stem cells to replace mine; then, if all went according to plan, these cells would grow into a new immune system to seek and destroy my cancer cells.

As a result of the transplant, all of my childhood vaccinations became ineffective. I was instructed to stay in isolation for at least four months in order to avoid infectious and possibly deadly diseases like influenza. Consequently, I have been quarantined since December.

Just a day before writing this, a friend told me that Im a trendsetter.

I knew very little about viruses before the coronavirus came alongonly that they were microscopic infectious organisms that invade living cells and then reproduce. In an effort to review what I had been (mostly unconsciously) protected from before transplant, I Googled the Centers for Disease Control and Prevention (CDC) and found a piece entitled, Vaccines for children: Diseases you almost forgot about.

I was reminded that most of us had vaccines as children for some of the nastiest viruses, including polio, which invades the brain and spinal cord and leads to paralysis; tetanus, a potentially fatal disease that causes lockjaw; whooping cough, which can lead to violent coughing that makes it difficult to breathe; and many more.

Most older adults are familiar with chicken pox, mumps and measles. I had two of them as a young teenager. One that I forgot about is diphtheria, which affects breathing or swallowing and can lead to heart failure, paralysis and death. There are several more.

I imagined the panic that parents must have felt and the pain that young children must have experienced before vaccines were discovered to prevent these horrible infectious diseases.

For the time being, I cannot replace my old vaccines. I must wait for at least one year while my new immune system gets stronger.

The idea of being in isolation and maintaining a safe social distance for a few months post-transplant made sense to me. I was well prepared by doctors and nurses and I knew my wife would be a great caregiver, so I thought I could do the time.

And then, the coronavirus came along.

For me, being quarantined was an old hat by the time a national emergency was declared and everything started to shut down. I learned that this new virus main target was the lungs and people older than 60 years with underlying health conditions were its primary targets.

I fit the bill and knew that Id have to do more time: at least another three months, my transplant doctor told me. The only difference is that this time, hundreds of millions of people would be joining me.

I was well-prepared before and after my transplant. I knew why I had to self-isolate and for how long. No one, including me, was prepared for COVID-19 and the mass quarantine that it now requiresnot only to protect oneself and ones family, but also to protect strangers. Mostly older strangers like me.

Scientists and other health professionals were the heroes of viral epidemics gone by. I do believe we will get through this, with people like immunologist Dr. Anthony Fauci leading the way.

Still, the unknown is what is most frightening. We all want answers, yet some remain illusive at the moment. This is an opportunity for all of us to strengthen our tolerance for ambiguity.

When will this end? No clue. Will it come back? No idea.

Although my new immune system needs more time to protect me, I just found out after a PET scan that Im in complete remission from my cancer.

Will it come back? No idea.

We are all in the same boat, living in uncertainty, whether young or old, healthy or unwell. As Plato said, Be kind, for everyone you meet is fighting a harder battle.

Andrew Malekoff is the executive director of North Shore Child and Family Guidance Center. To find out more, call 516-626-1971 or visit http://www.northshorechildguidance.org.

Go here to see the original:
A Quarantine Trendsetter - Long Island Weekly News

What We Know About Masks and the New Coronavirus – The New Yorker

By Stem Cell Doctors

So, going back to your question about the argument against the public wearing masks, I think that there was a mixture of concern that the public would hoard and that it would create alarm. But, to this point, we are in alarming circumstances, and the risk is non-zero. Lets say in the worst-case scenario that masks only offer fifty-per-cent protection. Well, fifty per cent is better than zero. And it seems to me, more and more, that the C.D.C. and the White House have come around to the idea that people should be wearing masks.

The other arguments I have read against them were about people scratching and touching their faces more, or about the difficulty of cleaning them, which introduces another risk.

If we ask the public to wear masks, whatever masks they are, we need a simple decontamination protocol. Because what we dont want is people to wear masks, and feel safe, whereas, in fact, they are collecting respiratory droplets. So we need a simple decontamination protocol.

What about cleaning masks? The C.D.C. says that they should be routinely washed, and that a washing machine should suffice.

You should follow the C.D.C. recommendations, but Im not aware of a lot of empirical data about whether washing degrades the fibres, and it would be very helpful if someone produced that data. I am agnostic, to be honest. If washing works, it works. I am totally fine with washing. I would follow the C.D.C. recommendations.

Just to emphasize: I do not have empirical data that simple masks work for the coronavirus. But we do know they work for other respiratory viruses. So what we are trying to do is extrapolate. There is no empirical evidence that Im aware of that going to the grocery store with a mask will protect you more than anything else from the coronavirus. But with other viruses, including ones that behave similarly, it helps.

What sort of face coverings should we be using if we dont have access yet to professionally made masks?

The quick answer is that I dont know and we dont know. I would vastly prefer that if we are going to ask the public to use masks, the C.D.C. or someone should give us very clear guidelines on what works and what doesnt work. There is a study from Cambridge University in which they tested a number of household materials, ranging from cloth to linen, against the size of a typical respiratory droplet. The study suggested that T-shirts and pillowcases worked fine. Again, we are operating with little data. Surgical masks are the most effective in this study. Then a vacuum-cleaner bag and then a dish towel. Then a cotton-blend T-shirt. So that is probably a reasonable item to use in a double layer.

The problem is that if we have a free-for-all, and say you can make your own, then there is no control over it. Some people will make things that are really good, and some people will make things that are terrible. And we will think they are all identical and move right along. It would be very helpful if we could standardize this and have a decontamination protocol for public use.

Has the science changed on masks at all recently? Or has this always been what it has been?

There is more science now. There are more papers for SARS, which show that, in the hospital, a simple surgical mask, in conjunction with hand hygiene and social distancing, vastly decreased the infection rate. The problem with science is that it cant catch up with what people are doing on the side. If everyone says they are going to use their own material, then science cant catch up with it, because we dont know what you are using. So there is more science, but the science has to go hand in hand with the social shifts. And it would seem to me that, rather than the President saying to cover your mouth with a scarf, having a scientific, centralized way to distribute it, produce it free of charge, and make everyone wear it, and have a decontamination protocol would be crucial.

Make everyone wear it, or suggest that they do?

I would suggest it, and if it really makes a dent, then put out a public-service announcement saying everyone should wear it. You cant force people to adopt behaviors in this country, although you can make it very uncomfortable for people who show up without masking because of social pressures. But I dont think it should be compulsory. I do think that, given the seriousness of what is going on, given the paralysis in the economy, and the desire for people to get back to work, I think there should be some sense of social responsibility, and if it really decreases the chance of infecting others and yourself, and if people agree universally to wear it, I think we could potentially convince the vast majority of the people to wear a mask.

Does this contradict what you said earlier about not wanting to shame people who dont wear it? Could we get to a point where we should be shaming people who dont?

I think shame is not the best mechanism for getting people to wear it. I think the better mechanism is for everyone to understand that there is a sense of social responsibility that they have, and adopting that social responsibility is part of what we do as a country to prevent economic collapse. If we dont get back to work by June or Julyhopefully, there will be medicines by then. But there will not be vaccines, and if we want to get back to work by June or July, I strongly suggest that we find mechanisms by which we can get back to work with masks.

Lots of evidence has shown that masked countries are doing better than unmasked ones in terms of spread. Do you attribute that to the masks?

Its very hard, because there is no trial and we have to believe the evidence at face value. There was a meme going around Twitter showing that countries with masks were doing better, but then someone superimposed that same meme and instead of masks they wrote bubble tea and no bubble. It is suggestive, but it is an unknowable, because no one did the experiment, and the scientist in me has to say that its an unknowable because there is no direct evidence that the countries wearing masks were more successful in decreasing the rise in infections.

And, in South Korea, say, it could be about something else, like testing.

It could be about testing. Yes.

Is mask wearing something that would generally be healthy and cut down on other diseases and flu deaths? Is this a societal change we should be making or thinking about apart from the coronavirus?

We know, again, from a vast amount of scientific evidence that viruses that are secreted through respiratory secretions and cough droplets, including influenza and SARS, are decreased in their exposure when people wear masks. So, under conditions when the infections are spreading fast, the evidence suggests that mask wearing really decreases the chance of infecting others and getting infected yourself. And the return on the so-called R0 of the virus may be quite large. So I think in conditions such as now, when there is exponential spread of the virus, I think that would be the right thing to do.

Here is the original post:
What We Know About Masks and the New Coronavirus - The New Yorker

TISSUE REGENERATION TECHNOLOGIES Announces That Its First Coronavirus Clinical Trial Has Been Initiated Utilizing Unfocused Shockwave Therapy…

By Stem Cell Doctors

(MENAFN - Newswire) ATLANTA,April 11, 2020(Newswire.com) - Tissue Regeneration Technologies (TRT) announced today an important addition to our patent family to potentially aid in the fight against the Coronavirus. This patent applies the known mechanisms of action of unfocused shockwaves against this deadly virus. It is documented that the application of shock waves can produce the following effects in vivo:

Stem cell activation

Modulation of inflammation

Blood flow improvement

Antimicrobial and antiviral

Dislodging, liquefaction and dilution of viscous fluids such as phlegm

All of these effects may aid in the fight against the Coronavirus. The last bullet point may allow for life-threatening mucous to be expelled more efficiently. As shockwaves pass through tissue types with differing acoustic properties (lung tissues and thick mucus produced by COVID type viruses), energy is released at the interfaces, which is theorized to contribute to the dislodging of mucus that has been observed immediately after treatment. Additionally, the known anti-inflammatory properties of shockwaves may modulate the inflammatory overreaction initiated by COVID-19. Finally, the reparative properties of Shockwaves, including the activation of resident stem cells, may aid in the recovery and regeneration of damaged lung tissue.

John Warlick, CEO states, 'the most exciting development is that we have initiated our first clinical trial enrolling those patients where both ventilators and ECMO (Extracorporeal Membrane Oxygenation) have failed to stabilize the patient. Based on the fast-acting mechanism of action discussed above, we hope to release the initial results very soon. We have been very cautious to develop our unfocused Shockwave (SoftWave) therapy for the treatment of the lungs as there are many misconceptions about the risks associated with shockwaves and lung tissue developed from the thirty plus years of utilizing high energy, focused shockwaves to destroy kidney stones. TRT's unique, patented low energy unfocused shockwaves do not adversely affect lung tissue as previously feared. This has been demonstrated with extensive invitro and invivo trials.'

CEO John Warlick further states, 'TRT has assembled a team of doctors, engineers, and physicists to support this Herculean effort to eradicate the virus in the lungs. More importantly, TRT will release an open-source 'white paper' site for others to contribute to this project. This project is too critical to handle on our own. We need to enlist additional experts in this endeavor. We know shockwaves influence most of the known biologic pathways to disrupt viral replication and aid in the support of the patient's recovery. We are very confident in the outcome of our fight to destroy the effects of the virus.'

' Ironically, a virus is a very fragile agent. Others seek very elaborate, expensive technologies to fight viruses. Sometimes you just need a sonic hammer. At the most basic level, shockwaves are just a biologic hammer triggering a basic biological response.'

Pleasereview the attached PDF below for full release.

MENAFN1304202000704191ID1100019367

See more here:
TISSUE REGENERATION TECHNOLOGIES Announces That Its First Coronavirus Clinical Trial Has Been Initiated Utilizing Unfocused Shockwave Therapy...

Michael Schumacher health: The truth about the F1 champ’s recovery after a devastating head injury in 2013 – EconoTimes

By Stem Cell Doctors

Michael Schumachers exact health condition is still a mystery up to now. His familys efforts to guard him against the media and the public eyes proved to be successful as people dont really know how he is doing today. There is no single photograph of the F1 racing champ since suffering from a severe head injury while skiing in the Alps with his family in December 2013.

Today, most of what people know about Schumi came from his close friends or sometimes from the medical professionals who cared for or treated him. But is he really recovering well just like what his friends and family are saying?

Early days after the accident

Immediately after Michael Schumacher bumped his head on a rock while skiing with his son, he was found unconscious due to traumatic head injury. He was airlifted to Hospital of Moutiers and then brought to Grenoble University Hospital Center, a bigger medical facility where he could get the treatment he needed at that time.

Doctors declared him in critical condition due to the severity of his brain trauma. Before 2014, he was put into an induced coma so he could be saved. He underwent brain surgery to stop the bleeding in his head.

There were reports that he passed away already, but the Grenoble University Hospital denied the rumors and announced on February 14 that Michael Schumacher is still alive. Since then, theres a media blackout about Schumacher but he was said to have woken up already after six months in a comatose state.

"He is sleeping, he looks normal and he showed a few responses with his mouth," Express quoted Felipe Massa, a Ferrari teammate who visited Schumi in the hospital. "I was very happy to be able to spend some time with him. I really hope that he will again be able to enjoy life."

The truth on Schumis condition today

Over six years after his accident, it was said that Michael Schumacher is recovering well as his family has been taking good care of him. It was claimed that he underwent stem-cell therapy in September last year but it appeared that this did not help him much.

As per The Daily Mail, the surgeon who performed the procedure on the F1 legend stated that he doesnt perform miracles which could mean that the treatment, even if it is considered as one of the breakthroughs in this age, did not heal Michael Schumacher. In another report, a surgeon stated that Schumi is very different now as the truth is - because of his prolonged medication and illness, his health is deteriorating.

"We must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure," Nicola Acciari, a surgeon, told Ovacion Uno. All as a result of the brain trauma he suffered."

View post:
Michael Schumacher health: The truth about the F1 champ's recovery after a devastating head injury in 2013 - EconoTimes

Michael Schumacher health: Timeline of F1 champion’s recovery bid – Express.co.uk

By Stem Cell Doctors

Michael Schumacher retired in 2012 as a seven-time F1 world champion and is widely regarded as one of the sport's greatest drivers of all time. However, the following year, the German racer suffered traumatic head injuries while on a skiing trip with his family.

Schumacher - who was wearing a helmet - fell and hit his head on a rock in the French Alps.

The 51-year-old has not been seen in public since the accident and updates on his health have been scarce.

December 29, 2013: Schumacher is airlifted to Hospital of Moutiers following the accident and later transported to Grenoble University Hospital Centre, where doctors said he was "suffering a serious brain trauma with coma on his arrival, which required an immediate neurosurgical operation".

December 30, 2013: Schumacher is said to be in "critical condition" as surgeons operate to stop brain haemorrhaging and treat intracranial pressures.

The former F1 star is placed in a medically induced coma.

ALSO SEE: What Michael Schumacher once told Bernie Ecclestone revealed by legend

January 1, 2014: Schumacher's condition is said to have improved slightly after the second operation but doctors added he was "not out of danger".

January 7, 2014: Schumacher's wife, Corinna, speaks publically for the first time since her husband's accident.

In a statement, she asked media at the Grenoble hospital to leave to "ease the burden on the doctors and the hospital so that they can do their work in peace".

She added: "Please also leave our family alone."

January 31, 2014: Doctors begin to gradually wake Schumacher up from the medically induced coma.

February 2014: Grenoble University Hospital confirm that Schumacher is still alive following reports the former F1 driver had died.

Schumachers agent, Sabine Kehm, says he is still in the wake-up phase from an induced coma.

Former Ferrari team-mate Felipe Massa also visits Schumacher in hospital and provides a brief update.

"He is sleeping, he looks normal and he showed a few responses with his mouth," said Massa.

"I was very happy to be able to spend some time with him. I really hope that he will again be able to enjoy life."

London neurosurgeon Colin Shieff says it is unlikely Schumacher will make a full recovery.

"The fact that he hasn't woken up implies that the injury has been extremely severe and that a full recovery is improbable," said Shieff.

March 2014: Kehm says there are "small and encouraging signs" the German's condition is improving.

Schumacher is moved to the University Hospital of Lausanne in Switzerland, close to his family home in Geneva.

June 2014: Schumacher is no longer in a medically induced coma.

July 2014: Corinna says her husband has begun to recognise her voice.

September 2014: Schumacher's recovery continues at his private home in Geneva, Switzerland.

A statement read: "Michael's rehabilitation will take place at his home.

"Considering the severe head injuries he suffered, progress has been made in the past weeks and months. There is still, however, a long and difficult road ahead."

2015: FIA president Jean Todt says the former Ferrari driver is "still fighting".

2016: Kehm says Schumacher's family are struggling to come to terms with the accident but hope he will "one day be back with us".

2017: Schumacher's lawyer was forced to tell a court the F1 legend "cannot walk" after an article by German magazine Bunte claimed he was walking. Bunte magazine had to pay 50,000 in damages.

2018: Corinna issues a brief update.

"It is good to receive so many kind wishes and other well-intentioned words - which is a great support for our family," she says.

"We all know Michael is a fighter and will not give up."

2019: Jean Todt, Schumacher's former Ferrari boss, says the star is "making good progress".

"Im always careful with such statements, but its true," said Todt. "I saw the race together with Michael Schumacher at his home in Switzerland."

Schumacher reportedly goes to the Georges-Pompidou hospital in Paris to undergo pioneering stem cell treatment.

The hospital neither confirms nor denies this, however, an unnamed nurse tells French outlet Le Parisien that Schumacher is conscious after a stem-cell procedure.

2020: Nicola Acciari, a leading neurosurgeon, says "we must imagine a person very different from the one we remember on the track, with a very altered and deteriorated organic, muscular and skeletal structure".

"All as a result of the brain trauma he suffered," she added.

See the original post here:
Michael Schumacher health: Timeline of F1 champion's recovery bid - Express.co.uk

Stem Cell Characterization Kits Market Prospects & Upcoming Trends and Opportunities Analyzed for Coming Years – The Cloud Tribune

By Stell Cell Research

Stem cells are biological cells that can be converted into specific type of cells as per the bodys requirement. Stem cells are of two types, i.e., adult stem cells and embryonic stem cells. Stem cells can be used to treat various diseases such as cancer, neurodegenerative disorder, cardiovascular disorder and tissue regeneration. Stem cell characterization is the initial step for stem cell research. Stem cell characterization is a challenging and also an evolving process. Stem cell characterization kits are used for identification of stem cell biology markers. In stem cell characterization, stem cell biology marker profiles differ based on their species, maturity and site of origin. Stem cell characterization kit is required to understand the utility of the stem cells in downstream experiments and to confirm the pluripotency of the stem cell.Request Free Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=2691

Based on type of stem cell, the stem cell characterization kits market is segmented into:Stem Cell Characterization Kits for Adult Stem CellsStem Cell Characterization Kits for Induced Pluripotent Stem CellsStem Cell Characterization Kits for Mesenchymal Stem CellsStem Cell Characterization Kits for Neural Stem CellsStem Cell Characterization Kits for Hematopoietic Stem CellsStem Cell Characterization Kits for Umbilical Cord Stem CellsStem Cell Characterization Kits for Human Embryonic Stem CellsBased on application, the stem cell characterization kits market is segmented into:ResearchDrug Discovery & DevelopmentRegenerative Medicine

Based on end user, the stem cell characterization kits market is segmented into:Biopharmaceutical CompaniesContract Research OrganizationsAcademics and Research InstitutesBiotechnology CompaniesHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=2691

Examples of some of the key participants in the stem cell characterization kits market identified across the value chain include Merck KGaA, Celprogen, Inc., Creative Bioarray, Thermo Fisher Scientific Inc., BD Biosciences, R&D Systems, Inc., System Biosciences, Cosmo Bio USA, BioCat GmbH, and DS Pharma Biomedical Co., Ltd.Pertinent aspects this study on the Stem Cell Characterization Kits market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Stem Cell Characterization Kits market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Stem Cell Characterization Kits market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Stem Cell Characterization Kits market? Which key end-use industry trends are expected to shape the growth prospects of the Stem Cell Characterization Kits market? What factors will promote new entrants in the Stem Cell Characterization Kits market? What is the degree of fragmentation in the Stem Cell Characterization Kits market, and will it increase in coming years?

Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Link:
Stem Cell Characterization Kits Market Prospects & Upcoming Trends and Opportunities Analyzed for Coming Years - The Cloud Tribune

Gracell to Present the First-in-human, Universal TruUCAR GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR…

By Stell Cell Research

SUZHOU, Chinaand SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of Universal TruUCAR GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) was accepted for plenary oral presentation at the America Association for Cancer Research (AACR) Annual Meeting.

This year's AACR presentations are moved to be held virtually to allow sharing the data in a timely fashion. A series of online sessions featuring presentations will be provided. Gracell will report the clinical safety and efficacy of GC027, an off-the-shelf CAR-T product based on Gracell's TruUCAR technology, for treatment of adult T-ALL patients.

"We are very pleased that AACR has accepted the phase I results of GC027, a first-in-human off-the-shelf TruUCAR product for plenary oral presentation. Gracell's proprietary TruUCAR platform was protected with patents of novel designs and unique features. Remarkably, GC027 derived from HLA unmatched donor's cells, is a monotherapy without co-administration of other immunosuppressive drug." said Dr. William CAO, founder and CEO of Gracell. "We are pleased to share thefirst-in-human phase I data with the scientific community."

Presentation: Safety and efficacy clinical study of TruUCART GC027: the first-in-human, universal CAR-T therapy for relapsed/refractory T-cell acute lymphoblastic leukemiaAbstract #9564Online live section: Apr. 27-28, EDT

About GC027GC027 was manufactured fromT cells of human leukocyte antigen (HLA) unmatched healthy donors using TruUCAR technology. TruUCAR allows the allogeneic CAR-T cells to proliferate and persist in HLA-unmatched patients (recipients) with minimized risk of graft-versus-host-disease (GvHD). GC027 is currently being developed as an investigational, off-the-shelf CAR-T cell therapy for treatment of T cell malignancies. The use of HLA unmatched healthy donor's cells may improve efficacy and reduce production time, available for off-the-shelf use in a timely manner.

About TruUCARTruUCAR is Gracell's proprietary and patented platform technology, with selected genes being edited to avoid GvHD and immune rejection without using strong immunosuppressive drugs. In addition to T-ALL antigen, the platform technology can also be implemented for other targets of hematological malignancies.

About T-ALLT - Lymphoblastic Leukemia (T-ALL) is an aggressive form of acute lymphoblastic leukemia, with a diffuse invasion of bone marrow and peripheral blood. In 2015, T-ALL affected around 876,000 people globally and resulted in 110,000 deaths worldwide. T-ALL compromises about 15%-20% of all children and adult acute lymphoblastic leukemia[1].Current standard of care therapies for T-ALL are chemotherapy and stem cell transplantation. 40-50% of patients will experience relapse within two years following front line therapy with limited treatment options available[2] [3]. Treatment of relapsed and refractory T-ALL remains a high unmet medical need.

About GracellGracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biotech company, committed to developing highly reliable and affordable cell gene therapies for cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR, TruUCAR (off-the-shelf CAR), Dual CAR and Enhanced CAR-T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

CONTACT:

Linc HEBusiness Development and Public RelationsLinc.he@gracellbio.com+86-21-6403-1375

[1] Pediatric hematologic Malignancies: T-cell acute lymphoblastic Leukemia, Hematology 2016[2] Progress and innovations in the management JAMA Oncol 2018[3] Defining the course and prognosis of adults with acute lymphoblastic leukemia, Cancer 2010

View original content to download multimedia:http://www.prnewswire.com/news-releases/gracell-to-present-the-first-in-human-universal-truucar-gc027-therapy-for-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-at-the-aacr-annual-meeting-301039311.html

SOURCE Gracell

Read the original:
Gracell to Present the First-in-human, Universal TruUCAR GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR...

Stem Cell Therapy Market report edited by leading research firm – WhaTech Technology and Markets News

By Stell Cell Research

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025).

The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world.

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market.

Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Stem Cell Therapy market. The study report covers all the recent developments and innovations in the market for a Stem Cell Therapy.

The global keyword market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market.

These strategies have an impact on the overall market.

Browse the complete report @ http://www.adroitmarketresearch.com/industrapy-market

Global Stem Cell Therapy market is segmented based by type, application and region. Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into, Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Based on application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into, Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

The research report on global Stem Cell Therapy market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global Stem Cell Therapy market.

Study report covers all the geographical regions where competitive landscape exists by the players such as North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts.

Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

For Any Query on the Stem Cell Therapy Market: http://www.adroitmarketresearch.com/contactbuying/691

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Stem Cell Therapy Market report edited by leading research firm - WhaTech Technology and Markets News

LILLEY: Trudeau government needs to stop taking COVID orders from WHO – Toronto Sun

By Stell Cell Research

Some days it really does feel like Canada has farmed out its entire health policy during this COVID-19 crisis to the World Health Organization.

From the early days, answers to questions on testing, on the spread of the virus, on approving treatments or even rapid testing, have been to cite what the WHO recommends.

That is nothing short of a dereliction of duty by Canadas top health officials.

The latest example is the decision of Health Canada not to approve a cheap and rapid test for COVID-19, one made right here in Canada, because of what the WHO says. BTNX Inc. of Markham, Ont. makes a test that can have results in 15 minutes and costs just $10 a piece.

The test cant be used for early detection but can confirm COVID-19 for people who have been showing symptoms for several days. It also tests for anti-bodies to determine if someone has already had the disease and therefore is possibly immune.

Despite the sale of this test kit in the U.S., the U.K. and across Europe, Health Canada turned the company down this past week. As CBC reported, the company was rejected by Health Canada over the advice given by the WHO.

In an email to CBC News, Health Canada said it is following the advice of the World Health Organization, which does not currently recommend serological (blood) tests for clinical diagnosis, CBC reported on Sunday.

Let me get this straight: We have a company that can provide accurate results using a blood test and we wont use it because an international body in Geneva says no?

Can you imagine that being the case when Banting and Best discovered how to extract insulin and treat diabetics at their University of Toronto lab? Or the invention of Pablum to fight off malnutrition in the 1930s?

Would Canadian doctors and researchers have had breakthroughs in open heart surgery, stem cell transplants, vaccines for childhood diseases, gene therapies, treatments for stroke, cystic fibrosis, HIV and more if we had to simply follow WHO guidelines?

No, in fact, following the rules of a bureaucratic organization like the WHO is the opposite of what researchers do.

Im not for a moment advocating that Canada should ignore the WHO, should play no part in it. The WHO has a role to play but that role is not in setting health policy for Canada.

Were we a less developed country with a less robust medical system, without more than a century of continuously evolving medical research, then perhaps listening to the WHO first and following their advice would make sense. For Canada it does not, it slows things down, it stops innovation.

Could and should Canada be working in coordination with the WHO? Sure, but not following their orders. This is an organization that has already been shown to have been slow off the mark by believing misinformation from the Chinese government at the start of this outbreak.

Sadly, though, whether the answers have come from Health Canada bureaucrats, the chief medical officer, the health minister or the prime minister, too often what Canadians have been told is a series of WHO talking points.

Canada has the medical ingenuity, the depth of research and the quality of doctors needed to chart our own path that at times will follow the WHO and at other times diverge. When time is of the essence in finding better ways to test, better ways to treat and better ways to counter the spread of this virus, Ill take Canadian doctors over a United Nations body in far off Geneva any day.

Lets hope the Trudeau government starts realizing that they should trust and champion Canadas medical community as well.

blilley@postmedia.com

View original post here:
LILLEY: Trudeau government needs to stop taking COVID orders from WHO - Toronto Sun

Cell Culture Protein Surface Coating Market to Witness Robust Expansion by 2025 – Germany English News

By Stell Cell Research

Global Cell Culture Protein Surface Coating Market: Snapshot

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering.

Thus, the growing scope of cell cultures in various applications has led to the development of the 3D cell culture technique, which has been considered one of the key factors responsible for the overall past development of the cell culture protein surface coatings market. Earlier, only a meager percentage of researchers preferred using 3D cell culture technique for drug discovery. However, there has been a dynamic shift from the traditional methods to the current cell culture methods.

Moreover, commercial production of drugs and biologics such as proteins, antibodies, and vaccines using cell culture has helped expand the scope of the latter in the global market. Commercial production has provided extensive business opportunities to manufacturers in the global market. Diverse applications of stem cells such as development of bone grafts and artificial tissue are also expected to fuel the demand for cell culture protein surface coatings over the forecast period. In addition, increasing cell culture applications in toxicology studies and cell-based assays are further pushing the growth of the market.

Global Cell Culture Protein Surface Coating Market: Overview

Cell culture protein surface coatings help in improving cell attachment, growth, and differentiation. They facilitate consistent performance in various cell-based assays and in-vitro culture by improving cell adhesion. A variety of adhesion proteins and other biological materials derived from various sources are being used to enhance performance in cell culture, especially in cell lines that are hard to attach, such as transfected cells. The major types of cell culture are animal-derived protein, human-derived protein, synthetic protein, and plant-derived protein. Good cell attachment has gained increased significance in recent years for improving the recovery of cells from frozen cultures and increasing the stability of attached surfaces. With constant advances in stem cell therapies, a number of advanced protein surface coatings have emerged to study stem cells and to further the potential of regenerative medicine. These developments have positively affected the growth of the global cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Key Trends

The increasing focus of numerous biotechnology companies and research laboratories on stem cell research to develop therapies for a range of chronic diseases is a key factor propelling the cell culture protein market. Considerable investment by the governments of various countries to fund several R&D activities related to regenerative medicine has fuelled the market. Coupled with this, the rising demand for biopharmaceutical products such as antibodies, vaccines, and drugs has stimulated the demand for cell culture protein surface coatings. The growing research on stem cells for finding therapies for various cardiovascular and neurological diseases is expected to boost the market in the coming years. The growing prominence of 3D cell culture over 2D cell cultures is expected to unlock exciting opportunities in the cell culture protein surface coating market.

Global Cell Culture Protein Surface Coating Market: Market Potential

The American Heart Association (AHA), together with the Paul G. Allen Frontiers Group, announced in April, 2017 two grantseach worth US$1.5 millionto scientists working on cardiovascular extracellular matrix (ECM) research. Interested researchers have to apply for grants by May 10, and each of the two winners will be entitled to the magnanimous sum.

The ECM regulates all vital cell functions and is considered a highly useful biomaterial for investigators. This can be applied as a stable coating to be used in a variety of cell cultures. The initiative focused on investigating the role of ECM in the initiation and progression of a number of cardiovascular diseases, such as hypertensive heart disease, ischemic heart disease, cardiomyopathies, congenital cardiovascular malformations, and atherosclerosis and vascular diseases. The funding will further the investigation into the diagnosis, prevention, and treatment of cardiovascular diseases. One of the most commonly used protein surface coatings used in ECM is collagen, which facilitates cell adherence, growth, migration, differentiation, and proliferation. The major research initiatives, opine the AHA, will be greatly useful in setting up a new paradigm in research in cell structure in biosciences.

Global Cell Culture Protein Surface Coating Market: Regional Outlook

North America is a prominent market for cell culture protein surface coatings and is expected to exhibit significant growth over the forecast period. The impressive growth in the regional market is attributed to the presence of a robust healthcare infrastructure and considerable advances in stem cell research. In addition, the soaring demand for regenerative medicines for a range of autoimmune therapies is expected to fuel the demand for surface coatings for improving the performance of in-vivo culture.

The Asia Pacific market for cell culture protein surface coating is poised to offer lucrative avenues for players in the market. Favorable regulations for biologics development and a burgeoning biotechnology industry are the factors expected to lead to substantial demand for cell culture protein surface coatings.

Global Cell Culture Protein Surface Coating Market: Competitive Analysis

The market is fairly competitive due to the presence of a large number of regional and global vendors. Leading vendors are actively focused on providing solutions having cell attachment ability and promoting in-vitro cell functions for a variety of cell types to gain competitive edge over others. Leading players operating in this market include Sigma-Aldrich Corporation, Agilent Technologies, Thermo Fisher Scientific, EMD Millipore, Corning Incorporated, Biomedtech Laboratories Inc., Neuvitro Corporation, and Progen Biotechnik GmbH.

Excerpt from:
Cell Culture Protein Surface Coating Market to Witness Robust Expansion by 2025 - Germany English News

→←